Renhe Pharmaceutical: Announcement on the wholly-owned subsidiary obtaining the drug registration certificate for Qingfeitang Granules
Securities code: 000650 Securities abbreviation: Renhe Pharmaceutical Announcement number: 2026-029
Renhe Pharmaceutical Co., Ltd.
Announcement on the wholly-owned subsidiary obtaining the Qingfeitang Granule Drug Registration Certificate
The Company and its directors and senior managers guarantee that the information disclosed is true, accurate and complete, and that there are no false records, misleading statements or major omissions.
Recently, Jiangxi Zhangshu Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Renhe Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company"), received the "Drug Registration Certificate" for Qingfeitang Granules approved and issued by the State Food and Drug Administration (hereinafter referred to as the "NMPA"). The relevant information is now announced as follows:
1. Basic information about drugs
Drug name: Qingfeitang Granules
Main ingredients: Scutellaria baicalensis, mulberry bark, fritillary, bitter almond, etc.
Dosage form: granules
Specifications: Each bag is equivalent to 15.81g of slices
Registration classification: Traditional Chinese Medicine Category 3.1
Is it exclusive: Exclusive
Prescription/Over-the-Counter Drugs: Prescription Drugs
Marketing authorization holder: Jiangxi Yaodu Zhangshu Pharmaceutical Co., Ltd.
Acceptance number: CXZS2500032
Certificate number: 2026S02130
Drug approval number: National Drug Approval Number C20260013
Approval conclusion: According to the "Drug Administration Law of the People's Republic of China", after review, this product complies with the relevant regulations on drug registration. This product is approved for marketing and a drug registration certificate is issued.
2. Other related information about drugs
The prescription of Qingfeitang granules comes from "Rejuvenation of All Diseases" written by Gong Tingxian, a famous physician in the Ming Dynasty. It is the 67th prescription in the "Catalogue of Ancient Classic Famous Prescriptions (First Batch)". The prescription consists of skullcap, platycodon, poria, orange, fritillary, mulberry bark, angelica, asparagus, gardenia, bitter almond, Ophiopogon japonicus, schisandra, licorice, ginger and jujube, a total of 15 It is composed of medicinal materials and has the effects of clearing away heat and moistening the lungs, lowering qi and resolving phlegm. It is mainly used to treat phlegm-heat cough. Symptoms include cough, wheezing, phlegm in the throat, thick and yellow phlegm, or hoarseness due to prolonged coughing, red tongue with yellow and greasy coating, and slippery and rapid pulse.
In accordance with the requirements of relevant regulations and guiding principles of the State Food and Drug Administration, the company developed Qingfeitang into Qingfeitang granules. After its launch, it will help promote the wider clinical use of ancient classic prescriptions, and help improve the clinical service level of traditional Chinese medicine and the convenience of patients' medication.
As of the date of this announcement, the company has invested approximately RMB 8 million (unaudited) in the research and development of the Qingfei Tang Granule project.
3. Risk warning
The approval of Qingfeitang granules for production and launch not only enriches the company's product lineup, but also helps enhance the market competitiveness of the company's products, creating favorable conditions for the company's sustained and steady development.
In view of the new drug registration approval for this variety, it is not expected to have a significant impact on the company's recent operating results. Since drug research and development, production and sales are easily affected by national policies, market environment and other factors, and are highly uncertain, investors are advised to make prudent decisions and pay attention to preventing investment risks.
Announcement hereby
Renhe Pharmaceutical Co., Ltd. Board of Directors
June 22, 2026